Filing Flows › Lyell Immunopharma (LYEL) › Q2 2026
Lyell Immunopharma (LYEL) Q2 2026 earnings results (second quarter 2026)
10-Q filed Aug 6, 2026
Lyell Immunopharma (LYEL) reported revenue of $4K for the second quarter 2026 (Q2 2026), -50% from a year earlier and +100% from the quarter before.
Lyell Immunopharma, Q2 2026: revenue $4K (-50% year over year), net loss $44.8M, operating cash flow −$33.9M. The chart follows the revenue to costs, profit and cash.
| Q2 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $4K | +100% | -50% |
| Operating profit | −$47.3M | — | — |
| Net earnings | −$44.8M | — | — |
| Operating cash flow | −$33.9M | — | — |
What changed
Revenue was $4K in Q2 2026, down 50% year over year and up 100% from the previous quarter.
Operating costs exceeded revenue by $47.3M, an operating margin of -1183425.0%. Total costs grew 0% against a revenue fall of 50%. The quarter ended with a net loss of $44.8M, wider than the previous quarter's $24.2M loss.
Operating cash flow was −$33.9M. Non-cash charges added back $2.2M of depreciation and amortization and $4.5M of share-based compensation. Working capital and other items added $4.1M. Capital expenditures of $256K exceeded it, leaving free cash flow of −$34.2M.
Questions
What was Lyell Immunopharma's revenue in the second quarter 2026?
Lyell Immunopharma (LYEL) reported revenue of $4K for the second quarter 2026 (Q2 2026), -50% from a year earlier and +100% from the quarter before.
Source: Lyell Immunopharma 10-Q on SEC EDGAR.